Baird raised the firm’s price target on Inspire Medical (INSP) to $236 from $230 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results whwre they announced the INSP V launch which will drive Q2 lower but full year guidance remains unchanged.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $174 from $195 at Wells Fargo
- Inspire Medical Systems: Hold Rating Amid Transition Challenges and Revised Price Target
- Inspire Medical Systems: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Inspire Medical Systems Reports Strong Q1 2025 Growth
- Inspire Medical reports Q1 EPS 10c, consensus (23c)